BRC-201 not checked

Boryung Biopharma Co., Ltd. · TG-1000

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“BRC-201 (pixavir marboxil) 20 mg capsules administered orally as a single dose of 40 mg (2 capsules) for participants weighing less than 80 kg or 80 mg (4 capsules) for participants weighing 80 kg or more.”In the company’s words, NCT07943390 on ClinicalTrials.gov
Tested for
Influenza
Main trialPhase 3
“This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection. The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.”In the company’s words, NCT07943390 on ClinicalTrials.gov
Other names
TG-1000 · Pixavir Marboxil

Other drugs for Influenza

All 30 drugs for Influenza

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Apr 2027 A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BRC-201

Following is part of Solo: you see every change to BRC-201 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in